Alpha 2.0
Login Register
» Articles » PMID: 35991834

Serial Liver Transaminases Have No Prognostic Value in Non-alcoholic Fatty Liver Disease

Overview
Journal Can Liver J
Specialty Gastroenterology
Date 2022 Aug 22
PMID 35991834
Authors
Julia Uhanova
Gerald Minuk
Kamila Premji
Natasha Chandok
Affiliations
Soon will be listed here.
Abstract

Background: Routine measurement of liver transaminases is common in the general monitoring of patients with non-alcoholic fatty liver disease (NAFLD), but there is little data to support the utility of this practice. The aims of this study were to determine how alanine aminotransferase (ALT) results vary over time in patients with NAFLD; and to determine if serial measurement of ALT is a useful clinical marker for progression of NAFLD.

Methods: Consecutive adult patients with NAFLD were followed prospectively in a tertiary liver disease clinic over a 15-year period. Clinicodemographic characteristics and the change in liver enzymes, liver function, and histopathology were followed over time. Paired test, chi-square test, analysis of variance (ANOVA), and logistic regression were performed to assess the relationship between ALT and severity of NAFLD, or development of cirrhosis or hepatocellular carcinoma (HCC).

Results/conclusion: A change in liver transaminases over time is not a useful metric in predicting outcomes in patients with NAFLD. Additionally, all stages of NAFLD are equally responsive to standard medical interventions of advocating for weight loss and correcting metabolic disturbances.

References
1.
Chandok N, Minuk G, Wengiel M, Uhanova J . Serum ferritin levels do not predict the stage of underlying non-alcoholic fatty liver disease. J Gastrointestin Liver Dis. 2012; 21(1):53-8. View
2.
Udell J, Wang C, Tinmouth J, FitzGerald J, Ayas N, Simel D . Does this patient with liver disease have cirrhosis?. JAMA. 2012; 307(8):832-842. DOI: 10.1001/jama.2012.186. View
3.
Lazo M, Hernaez R, Bonekamp S, Kamel I, Brancati F, Guallar E . Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ. 2011; 343:d6891. PMC: 3220620. DOI: 10.1136/bmj.d6891. View
4.
Manousou P, Kalambokis G, Grillo F, Watkins J, Xirouchakis E, Pleguezuelo M . Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int. 2011; 31(5):730-9. DOI: 10.1111/j.1478-3231.2011.02488.x. View
5.
Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E . Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005; 128(7):1898-906. DOI: 10.1053/j.gastro.2005.03.084. View